机构:[1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Oncol Dept, Beijing, Peoples R China[2]Chongqing Med Univ, Affiliated Hosp 1, Gastrointestinal Surg, Chongqing, Peoples R China重庆医科大学附属第一医院[3]Harbin Med Univ, Canc Hosp, GI Oncol, Harbin, Peoples R China[4]Sun Yat Sen Univ, Ctr Canc, Gastr Surg, Guangzhou, Peoples R China[5]Qingdao Univ, Affiliated Hosp, Gastrointestinal Surg, Qingdao, Shandong, Peoples R China[6]Fujian Med Univ, Union Hosp, Gastr Surg, Fuzhou, Peoples R China[7]Sun Yat Sen Univ, Affiliated Hosp 1, Gastrointestinal Surg, Guangzhou, Peoples R China中山大学附属第一医院[8]Fudan Univ, Shanghai Canc Ctr, Gastr Surg 1, Shanghai, Peoples R China[9]Zhejiang Canc Hosp, Univ Chinese Acad Sci, Canc Hosp, Colorectal Surg, Hangzhou, Peoples R China浙江省肿瘤医院[10]Hebei Med Univ North Gate, Hosp 4, Gen Surg, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院[11]Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Gastrointestinal Surg, Shanghai, Peoples R China[12]Fudan Univ, Zhongshan Hosp, Gen Surg, Shanghai, Peoples R China[13]Huazhong Univ Sci & Technol, Canc Ctr Union Hosp, Tongji Med Coll, Gastrointestinal Surg,Union Hosp, Wuhan, Peoples R China华中科技大学同济医学院附属协和医院[14]301 Mil Hosp, Chinese PLA Gen Hosp, Gen Surg, Beijing, Peoples R China[15]Xinjiang Med Univ, Affiliated Tumor Hosp, Gastrointestinal Surg, Xingjiang, Peoples R China[16]Sichuan Univ, West China Hosp, Gastr Canc Ctr, Chengdu, Peoples R China四川大学华西医院[17]Sun Yat Sen Univ, Affiliated Hosp 6, Med Oncol, Guangzhou, Peoples R China中山大学附属第六医院[18]Peking Univ Peoples Hosp, Gastrointestinal Surg, Beijing, Peoples R China[19]Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
第一作者机构:[1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Oncol Dept, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Li J.,Zhang J.,Zhang Y.,et al.Long-term updated outcomes of a phase II study of ripretinib vs. sunitinib in chinese patients with advanced gastrointestinal stromal tumor[J].ANNALS OF ONCOLOGY.2024,35:S1048-S1048.doi:10.1016/j.annonc.2024.08.1850.
APA:
Li, J.,Zhang, J.,Zhang, Y.,Qiu, H.,Zhou, Y....&Shen, L..(2024).Long-term updated outcomes of a phase II study of ripretinib vs. sunitinib in chinese patients with advanced gastrointestinal stromal tumor.ANNALS OF ONCOLOGY,35,
MLA:
Li, J.,et al."Long-term updated outcomes of a phase II study of ripretinib vs. sunitinib in chinese patients with advanced gastrointestinal stromal tumor".ANNALS OF ONCOLOGY 35.(2024):S1048-S1048